Cardiovascular Risk in Orthotopic Liver Transplantation (CAR-OLT) Score
Predicts the 1-year risk of a cardiovascular complication (cardiovascular death, or hospitalisation for MI, revascularisation, heart failure, AF, cardiac arrest, PE, TIA or stroke) after liver transplantation, from pre-transplant factors. Comorbidities are coded as history before transplant.
Score interpretation
CAR-OLT < 10: predicted 1-year cardiovascular complication risk < 5 %.
→ Standard pre-transplant cardiac evaluation per the transplant centre protocol.
CAR-OLT 10–15: predicted 1-year risk 6–8 %.
→ Standard pre-transplant cardiac evaluation; optimise cardiovascular risk factors.
CAR-OLT 16–30: predicted 1-year risk 10–26 %.
→ Enhanced cardiac evaluation and transplant-cardiology review; optimise before and monitor after transplant.
CAR-OLT 31–36: predicted 1-year risk 30–38 %.
→ Multidisciplinary transplant-cardiology review; intensive peri-operative cardiac planning.
CAR-OLT ≥ 37: predicted 1-year risk 40–45 % or more.
→ Multidisciplinary transplant-cardiology review of candidacy and peri-operative cardiac management.
Interpretation bands for the CAR-OLT. Apply clinical judgement and local guidance.
References
- VanWagner LB, et al. A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: the CAR-OLT score. Hepatology. 2017;66(6):1968–1979.
Related
Curated clinical cross-links plus same-class fallbacks.
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- SORT (Surgical Outcome Risk Tool) · Perioperative Risk
- Revised Cardiac Risk Index (RCRI / Lee Index) · Perioperative Risk
- ASA Physical Status Classification · Perioperative Risk
- Gupta Perioperative Risk for MI or Cardiac Arrest (MICA) · Perioperative Risk
- AUB-HAS2 Cardiovascular Risk Index · Perioperative Risk
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Tenecteplase · Cardiovascular Emergency
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.